OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation

Carlo Marchetti, Benjamin Swartzwelter, Fabia Gamboni, Charles P. Neff, Katrin Richter, Tania Azam, Sonia Carta, Isak Tengesdal, Travis Nemkov, Angelo D’Alessandro, Curtis Henry, Gerald S. Jones, Scott A. Goodrich, Joseph P. St. Laurent, Terry M. Jones, Curtis L. Scribner, Robert B. Barrow, Roy D Altman, Damaris B. Skouras, Marco GattornoVeronika Grau, Sabina Janciauskiene, Anna Rubartelli, Leo A.B. Joosten, Charles A. Dinarello

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Activation of the NLRP3 inflammasome induces maturation of IL-1β and IL-18, both validated targets for treating acute and chronic inflammatory diseases. Here, we demonstrate that OLT1177, an orally active β-sulfonyl nitrile molecule, inhibits activation of the NLRP3 inflammasome. In vitro, nanomolar concentrations of OLT1177 reduced IL-1β and IL-18 release following canonical and noncanonical NLRP3 inflammasome activation. The molecule showed no effect on the NLRC4 and AIM2 inflammasomes, suggesting specificity for NLRP3. In LPS-stimulated human blood-derived macrophages, OLT1177 decreased IL-1β levels by 60% and IL-18 by 70% at concentrations 100-fold lower in vitro than plasma concentrations safely reached in humans. OLT1177 also reduced IL-1β release and caspase-1 activity in freshly obtained human blood neutrophils. In monocytes isolated from patients with cryopyrin-associated periodic syndrome (CAPS), OLT1177 inhibited LPS-induced IL-1β release by 84% and 36%. Immunoprecipitation and FRET analysis demonstrated that OLT1177 prevented NLRP3-ASC, as well as NLRP3-caspase-1 interaction, thus inhibiting NLRP3 inflammasome oligomerization. In a cell-free assay, OLT1177 reduced ATPase activity of recombinant NLRP3, suggesting direct targeting of NLRP3. Mechanistically, OLT1177 did not affect potassium efflux, gene expression, or synthesis of the IL-1β precursor. Steady-state levels of phosphorylated NF-κB and IkB kinase were significantly lowered in spleen cells from OLT1177-treated mice. We observed reduced IL-1β content in tissue homogenates, limited oxidative stress, and increased muscle oxidative metabolism in OLT1177-treated mice challenged with LPS. Healthy humans receiving 1,000 mg of OLT1177 daily for 8 d exhibited neither adverse effects nor biochemical or hematological changes.

Original languageEnglish (US)
Pages (from-to)E1530-E1539
JournalProceedings of the National Academy of Sciences of the United States of America
Volume115
Issue number7
DOIs
StatePublished - Feb 13 2018
Externally publishedYes

Fingerprint

Inflammasomes
Nitriles
Interleukin-1
Inflammation
Costs and Cost Analysis
Interleukin-18
Caspase 1
Cryopyrin-Associated Periodic Syndromes
Immunoprecipitation
Adenosine Triphosphatases
Monocytes
Potassium
Oxidative Stress
Neutrophils
Chronic Disease
Phosphotransferases
Spleen
Macrophages
Gene Expression
Muscles

Keywords

  • Caspase-1
  • Interleukin-1
  • NLRP3

ASJC Scopus subject areas

  • General

Cite this

OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. / Marchetti, Carlo; Swartzwelter, Benjamin; Gamboni, Fabia; Neff, Charles P.; Richter, Katrin; Azam, Tania; Carta, Sonia; Tengesdal, Isak; Nemkov, Travis; D’Alessandro, Angelo; Henry, Curtis; Jones, Gerald S.; Goodrich, Scott A.; St. Laurent, Joseph P.; Jones, Terry M.; Scribner, Curtis L.; Barrow, Robert B.; Altman, Roy D; Skouras, Damaris B.; Gattorno, Marco; Grau, Veronika; Janciauskiene, Sabina; Rubartelli, Anna; Joosten, Leo A.B.; Dinarello, Charles A.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 115, No. 7, 13.02.2018, p. E1530-E1539.

Research output: Contribution to journalArticle

Marchetti, C, Swartzwelter, B, Gamboni, F, Neff, CP, Richter, K, Azam, T, Carta, S, Tengesdal, I, Nemkov, T, D’Alessandro, A, Henry, C, Jones, GS, Goodrich, SA, St. Laurent, JP, Jones, TM, Scribner, CL, Barrow, RB, Altman, RD, Skouras, DB, Gattorno, M, Grau, V, Janciauskiene, S, Rubartelli, A, Joosten, LAB & Dinarello, CA 2018, 'OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation', Proceedings of the National Academy of Sciences of the United States of America, vol. 115, no. 7, pp. E1530-E1539. https://doi.org/10.1073/pnas.1716095115
Marchetti, Carlo ; Swartzwelter, Benjamin ; Gamboni, Fabia ; Neff, Charles P. ; Richter, Katrin ; Azam, Tania ; Carta, Sonia ; Tengesdal, Isak ; Nemkov, Travis ; D’Alessandro, Angelo ; Henry, Curtis ; Jones, Gerald S. ; Goodrich, Scott A. ; St. Laurent, Joseph P. ; Jones, Terry M. ; Scribner, Curtis L. ; Barrow, Robert B. ; Altman, Roy D ; Skouras, Damaris B. ; Gattorno, Marco ; Grau, Veronika ; Janciauskiene, Sabina ; Rubartelli, Anna ; Joosten, Leo A.B. ; Dinarello, Charles A. / OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. In: Proceedings of the National Academy of Sciences of the United States of America. 2018 ; Vol. 115, No. 7. pp. E1530-E1539.
@article{05c8615110e54fc78521f037d54dc1b2,
title = "OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation",
abstract = "Activation of the NLRP3 inflammasome induces maturation of IL-1β and IL-18, both validated targets for treating acute and chronic inflammatory diseases. Here, we demonstrate that OLT1177, an orally active β-sulfonyl nitrile molecule, inhibits activation of the NLRP3 inflammasome. In vitro, nanomolar concentrations of OLT1177 reduced IL-1β and IL-18 release following canonical and noncanonical NLRP3 inflammasome activation. The molecule showed no effect on the NLRC4 and AIM2 inflammasomes, suggesting specificity for NLRP3. In LPS-stimulated human blood-derived macrophages, OLT1177 decreased IL-1β levels by 60{\%} and IL-18 by 70{\%} at concentrations 100-fold lower in vitro than plasma concentrations safely reached in humans. OLT1177 also reduced IL-1β release and caspase-1 activity in freshly obtained human blood neutrophils. In monocytes isolated from patients with cryopyrin-associated periodic syndrome (CAPS), OLT1177 inhibited LPS-induced IL-1β release by 84{\%} and 36{\%}. Immunoprecipitation and FRET analysis demonstrated that OLT1177 prevented NLRP3-ASC, as well as NLRP3-caspase-1 interaction, thus inhibiting NLRP3 inflammasome oligomerization. In a cell-free assay, OLT1177 reduced ATPase activity of recombinant NLRP3, suggesting direct targeting of NLRP3. Mechanistically, OLT1177 did not affect potassium efflux, gene expression, or synthesis of the IL-1β precursor. Steady-state levels of phosphorylated NF-κB and IkB kinase were significantly lowered in spleen cells from OLT1177-treated mice. We observed reduced IL-1β content in tissue homogenates, limited oxidative stress, and increased muscle oxidative metabolism in OLT1177-treated mice challenged with LPS. Healthy humans receiving 1,000 mg of OLT1177 daily for 8 d exhibited neither adverse effects nor biochemical or hematological changes.",
keywords = "Caspase-1, Interleukin-1, NLRP3",
author = "Carlo Marchetti and Benjamin Swartzwelter and Fabia Gamboni and Neff, {Charles P.} and Katrin Richter and Tania Azam and Sonia Carta and Isak Tengesdal and Travis Nemkov and Angelo D’Alessandro and Curtis Henry and Jones, {Gerald S.} and Goodrich, {Scott A.} and {St. Laurent}, {Joseph P.} and Jones, {Terry M.} and Scribner, {Curtis L.} and Barrow, {Robert B.} and Altman, {Roy D} and Skouras, {Damaris B.} and Marco Gattorno and Veronika Grau and Sabina Janciauskiene and Anna Rubartelli and Joosten, {Leo A.B.} and Dinarello, {Charles A.}",
year = "2018",
month = "2",
day = "13",
doi = "10.1073/pnas.1716095115",
language = "English (US)",
volume = "115",
pages = "E1530--E1539",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "7",

}

TY - JOUR

T1 - OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation

AU - Marchetti, Carlo

AU - Swartzwelter, Benjamin

AU - Gamboni, Fabia

AU - Neff, Charles P.

AU - Richter, Katrin

AU - Azam, Tania

AU - Carta, Sonia

AU - Tengesdal, Isak

AU - Nemkov, Travis

AU - D’Alessandro, Angelo

AU - Henry, Curtis

AU - Jones, Gerald S.

AU - Goodrich, Scott A.

AU - St. Laurent, Joseph P.

AU - Jones, Terry M.

AU - Scribner, Curtis L.

AU - Barrow, Robert B.

AU - Altman, Roy D

AU - Skouras, Damaris B.

AU - Gattorno, Marco

AU - Grau, Veronika

AU - Janciauskiene, Sabina

AU - Rubartelli, Anna

AU - Joosten, Leo A.B.

AU - Dinarello, Charles A.

PY - 2018/2/13

Y1 - 2018/2/13

N2 - Activation of the NLRP3 inflammasome induces maturation of IL-1β and IL-18, both validated targets for treating acute and chronic inflammatory diseases. Here, we demonstrate that OLT1177, an orally active β-sulfonyl nitrile molecule, inhibits activation of the NLRP3 inflammasome. In vitro, nanomolar concentrations of OLT1177 reduced IL-1β and IL-18 release following canonical and noncanonical NLRP3 inflammasome activation. The molecule showed no effect on the NLRC4 and AIM2 inflammasomes, suggesting specificity for NLRP3. In LPS-stimulated human blood-derived macrophages, OLT1177 decreased IL-1β levels by 60% and IL-18 by 70% at concentrations 100-fold lower in vitro than plasma concentrations safely reached in humans. OLT1177 also reduced IL-1β release and caspase-1 activity in freshly obtained human blood neutrophils. In monocytes isolated from patients with cryopyrin-associated periodic syndrome (CAPS), OLT1177 inhibited LPS-induced IL-1β release by 84% and 36%. Immunoprecipitation and FRET analysis demonstrated that OLT1177 prevented NLRP3-ASC, as well as NLRP3-caspase-1 interaction, thus inhibiting NLRP3 inflammasome oligomerization. In a cell-free assay, OLT1177 reduced ATPase activity of recombinant NLRP3, suggesting direct targeting of NLRP3. Mechanistically, OLT1177 did not affect potassium efflux, gene expression, or synthesis of the IL-1β precursor. Steady-state levels of phosphorylated NF-κB and IkB kinase were significantly lowered in spleen cells from OLT1177-treated mice. We observed reduced IL-1β content in tissue homogenates, limited oxidative stress, and increased muscle oxidative metabolism in OLT1177-treated mice challenged with LPS. Healthy humans receiving 1,000 mg of OLT1177 daily for 8 d exhibited neither adverse effects nor biochemical or hematological changes.

AB - Activation of the NLRP3 inflammasome induces maturation of IL-1β and IL-18, both validated targets for treating acute and chronic inflammatory diseases. Here, we demonstrate that OLT1177, an orally active β-sulfonyl nitrile molecule, inhibits activation of the NLRP3 inflammasome. In vitro, nanomolar concentrations of OLT1177 reduced IL-1β and IL-18 release following canonical and noncanonical NLRP3 inflammasome activation. The molecule showed no effect on the NLRC4 and AIM2 inflammasomes, suggesting specificity for NLRP3. In LPS-stimulated human blood-derived macrophages, OLT1177 decreased IL-1β levels by 60% and IL-18 by 70% at concentrations 100-fold lower in vitro than plasma concentrations safely reached in humans. OLT1177 also reduced IL-1β release and caspase-1 activity in freshly obtained human blood neutrophils. In monocytes isolated from patients with cryopyrin-associated periodic syndrome (CAPS), OLT1177 inhibited LPS-induced IL-1β release by 84% and 36%. Immunoprecipitation and FRET analysis demonstrated that OLT1177 prevented NLRP3-ASC, as well as NLRP3-caspase-1 interaction, thus inhibiting NLRP3 inflammasome oligomerization. In a cell-free assay, OLT1177 reduced ATPase activity of recombinant NLRP3, suggesting direct targeting of NLRP3. Mechanistically, OLT1177 did not affect potassium efflux, gene expression, or synthesis of the IL-1β precursor. Steady-state levels of phosphorylated NF-κB and IkB kinase were significantly lowered in spleen cells from OLT1177-treated mice. We observed reduced IL-1β content in tissue homogenates, limited oxidative stress, and increased muscle oxidative metabolism in OLT1177-treated mice challenged with LPS. Healthy humans receiving 1,000 mg of OLT1177 daily for 8 d exhibited neither adverse effects nor biochemical or hematological changes.

KW - Caspase-1

KW - Interleukin-1

KW - NLRP3

UR - http://www.scopus.com/inward/record.url?scp=85042015277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042015277&partnerID=8YFLogxK

U2 - 10.1073/pnas.1716095115

DO - 10.1073/pnas.1716095115

M3 - Article

C2 - 29378952

AN - SCOPUS:85042015277

VL - 115

SP - E1530-E1539

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 7

ER -